Opinion
Video
Author(s):
Key opinion leaders examine TYK2 inhibition and deucravacitinib, focusing on the mechanism of action, safety profile, and strategies for effective patient-provider communication regarding this treatment approach.
Deucravacitinib Shows Significant Efficacy and Safety in Phase 3b/4 Trial for Moderate to Severe Scalp Psoriasis
The Cutaneous Connection: An Inside Look of the Inclusive Atlas
Guselkumab Demonstrates Significant Skin Clearance in Hard-to-Treat Moderate Psoriasis Sites
The Cutaneous Connection: Episode 31- Molecular Targeting of Psoriasis Biologics
Facing Challenges in Pediatric Plaque Psoriasis
Available Psoriasis, Patient Involvement, and Holistic Treatment